Companies › AgelessRx
4 active drug programs in 21 registered trials: 9 Phase 2, 7 Phase 3, 3 Phase 4, 2 Phase 1; Other, Neurology, Infectious disease, Metabolic and endocrine.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Glutathione (GSH) Antioxidant | – | Phase 3 | Healthspan Improvement; Renal Failure | – |
| NAD+ (nicotinamide adenine dinucleotide) NAD+ biosynthesis precursor/cofactor | – | Phase 3 | Healthspan Improvement | – |
| Naltrexone Opioid receptors; mu/kappa/delta antagonist | OPRK1, OPRD1, OPRM1 | Phase 3 | Healthspan Improvement; Longevity; Human Immunodeficiency Virus; Obesity; Drug … | – |
| Sirolimus FK506-binding protein 1A inhibitor | FKBP1A | Phase 3 | Healthspan Improvement; Longevity | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07092618 | Sirolimus | Phase 2 | Longevity | Other | Aug 2025 |
| NCT07092618 | Naltrexone | Phase 2 | Longevity | Other | Aug 2025 |
| NCT07475546 | Sirolimus | Phase 3 | Healthspan Improvement | Other | Apr 2026 |
| NCT07475546 | Naltrexone | Phase 3 | Healthspan Improvement | Other | Apr 2026 |
| NCT07475546 | NAD+ (nicotinamide adenine dinucleotide) | Phase 3 | Healthspan Improvement | Other | Apr 2026 |
| NCT07475546 | Glutathione (GSH) | Phase 3 | Healthspan Improvement | Other | Apr 2026 |
| NCT04408313 | Naltrexone | Phase 2 | Opioid-use Disorder | Psychiatry | May 2026 |
| NCT07269873 | Naltrexone | Phase 1 | Healthy Adult Male and Female Volunteers | Other | Dec 2026 |
| NCT04649892 | Naltrexone | Phase 2 | Gaming Disorder | Other | Dec 2026 |
| NCT04678895 | Naltrexone | Phase 2 | Painful Diabetic Neuropathy | Neurology | Dec 2026 |
| NCT04464980 | Naltrexone | Phase 2 | Opioid Use Disorder (OUD) | Psychiatry | Dec 2026 |
| NCT06233799 | Naltrexone | Phase 3 | Methamphetamine-dependence | Psychiatry | Apr 2027 |
| NCT06620523 | Glutathione (GSH) | Phase 2 | Renal Failure | Cardiovascular | Jun 2027 |
| NCT05537935 | Naltrexone | Phase 4 | Human Immunodeficiency Virus | Infectious disease | Jun 2027 |
| NCT05968690 | Naltrexone | Phase 1 | Advanced Melanoma | Oncology | Sep 2027 |
| NCT06845124 | Naltrexone | Phase 2 | Alcohol Addiction | Psychiatry | Apr 2028 |
| NCT06620562 | Naltrexone | Phase 4 | Obesity; Drug | Metabolic and endocrine | Jun 2028 |
| NCT05827159 | Naltrexone | Phase 3 | Alcohol Use Disorder | Psychiatry | Aug 2028 |
| NCT05827159 | Naltrexone | Phase 3 | Alcohol Use Disorder | Psychiatry | Aug 2028 |
| NCT06426303 | Naltrexone | Phase 4 | Alcohol Use Disorder | Psychiatry | Dec 2028 |
| NCT07224009 | Naltrexone | Phase 2 | Metastatic Prostate Cancer | Oncology | Jan 2029 |
Adneuris Therapeutics HTA Trevi Therapeutics Palvella Therapeutics Acer Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.